TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Prostate cancer progression is navigated by the androgen receptor (AR) and transforming-growth factor-β (TGF-β) signaling. We previously demonstrated that aberrant TGF-β signaling accelerates prostate tumor progression in a transgenic mouse model of prostate cancer via effects on epithelial-mesenchymal transition (EMT), driving castration-resistant prostate cancer (CRPC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Prostate

Title: The Prostate

Publisher: Wiley

ISSN (Electronic): 1097-0045

ISSN (Print): 0270-4137

Publication date (Electronic): January 2019

Volume: 79

Issue: 1

Affiliations

[1 ] The Johns Hopkins Kimmel Cancer Center and Department of Medicine, Johns Hopkins University, Baltimore, Maryland.

[2 ] Department of Urology, University of Kentucky College of Medicine, Lexington, Kentucky.

[3 ] Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, Kentucky.

[4 ] Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, Kentucky.

Article

DOI: 10.1002/pros.23708

PubMed ID: 30155899

SO-VID: 49888fd1-4233-4354-8004-171c3e0cb586

History

Keywords: EMT,TGF-β inhibition strong,enzalutamide,therapeutic response

Data availability:

Keywords: EMT, TGF-β inhibition strong, enzalutamide, therapeutic response

Comments

Comment on this article

scite_

Cited by 26

See all cited by